- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04148352
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
October 2, 2023 updated by: Andrew J Long, PharmD
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab and Milk Oral Immunotherapy for the Treatment of Patients With Cow's Milk Allergy
This is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk.
The primary objective is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) compared to placebo improves the safety of milk OIT and rates of desensitization, defined as an increase in the proportion of subjects who pass a double-blind placebo-controlled food challenge (DBPCFC) to at least 2040 mg cumulative milk protein at week 18.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
116
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andrew Long, PharmD
- Phone Number: 650-521-7237
- Email: snpcenterallergy_scheduler@stanford.edu
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Phoenix Children's Hospital
-
Contact:
- Benjamin Wright, MD
- Phone Number: 480-301-4284
- Email: wright.benjamin@mayo.edu
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic
-
Contact:
- Benjamin Wright, MD
- Phone Number: 480-301-4284
- Email: wright.benjamin@mayo.edu
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University
-
Contact:
- Sayantani Sindher, MD
- Phone Number: 650-521-7237
- Email: snpcenterallergy_scheduler@stanford.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 4 to 50 years (inclusive)
- Clinical history of allergy to cow's milk or milk-containing foods
- Serum IgE to milk of >4 kUA/L within the last 12 months and/or a SPT to milk ≥6 mm compared to a negative control
- Experience clinical reaction at or before 444 mg cumulative protein dose of cow's milk protein on Screening DBPCFC
- No clinical reaction observed during the placebo (oat) Screening DBPCFC
- Subjects with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study
- Use of effective birth control by female participants of childbearing potential
Exclusion Criteria:
- Any previous exposure to dupilumab
- Known hypersensitivity to dupilumab or any of its excipients
- Known hypersensitivity to epinephrine or any of its excipients
- Allergy to oat (placebo in DBPCFC)
- History of severe anaphylaxis to cow's milk, defined as neurological compromise or requiring intubation
- Recent history of frequent severe, life-threatening episodes of anaphylaxis or anaphylactic shock as defined as 3 or more episodes of anaphylaxis within the past year
- Inability to tolerate biological (antibody) therapies
- Body weight <5 kg at the time of screening
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia (e.g., difficulty swallowing, food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension
- History of a mast cell disorder
- Established diagnosis of a primary immunodeficiency disorder
- Severe asthma or mild or moderate asthma if uncontrolled or difficult to control
- Current participation or within the last 4 months in any other interventional study
- Use of medication such as beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers
- Pregnant or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dupilumab
24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
|
Dupilumab injected every 2 weeks for 18 weeks
|
Placebo Comparator: Placebo
24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
|
Placebo injected every 2 weeks for 18 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects treated with dupilumab plus milk protein OIT vs placebo plus milk protein OIT who tolerate at least 2040 mg (cumulative) cow's milk protein during DBPCFC to milk at week 18
Time Frame: Week 18
|
DBPCFC is a double-blind, placebo-controlled food challenge
|
Week 18
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants who tolerate at least 1040 mg cumulative milk protein at week 18 DBPCFC
Time Frame: Week 18
|
Week 18
|
Proportion of participants who tolerate 4040 mg cumulative milk protein at week 18 DBPCFC
Time Frame: Week 18
|
Week 18
|
Proportion of participants who tolerate at least 1040 mg cumulative milk protein at week 24 DBPCFC
Time Frame: week 24
|
week 24
|
Proportion of participants who tolerate at least 2040 mg cumulative milk protein at week 24 DBPCFC
Time Frame: Week 24
|
Week 24
|
Proportion of participants who tolerate 4040 mg cumulative milk protein at week 24 DBPCFC
Time Frame: Week 24
|
Week 24
|
Change in the cumulative tolerated dose (CTD) of milk protein during DBPCFC from baseline to week 18 across cohorts as pairwise comparisons of all treatment groups
Time Frame: Baseline and week 18
|
Baseline and week 18
|
Change in the cumulative tolerated dose (CTD) of milk protein during DBPCFC from baseline to week 24 across cohorts as pairwise comparisons of all treatment groups
Time Frame: Baseline and week 24
|
Baseline and week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Andrew Long, PharmD, Stanford, Sean N. Parker Center for Allergy & Asthma Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2021
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
October 30, 2019
First Submitted That Met QC Criteria
October 30, 2019
First Posted (Actual)
November 1, 2019
Study Record Updates
Last Update Posted (Actual)
October 3, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-52976
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergies Food Milk
-
University of Colorado, DenverNational Institutes of Health (NIH)RecruitingPeanut Allergies | Tree Nut Allergies | Other Food AllergiesUnited States
-
University Hospital, AngersUnknown
-
Société des Produits Nestlé (SPN)CompletedShort Bowel Syndrome | Cow's Milk Protein Allergy | Eosinophilic Gastrointestinal Disorders | Malabsorption/Maldigestion | Multiple Food AllergiesUnited States
-
National Taiwan University HospitalUnknown
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
University of Missouri-ColumbiaTerminated
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
-
Federico II UniversityUnknown
-
Universitaire Ziekenhuizen KU LeuvenRecruitingCow Milk Allergy | Food AllergyBelgium
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
SanofiRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolyposisFrance, Réunion
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationRecruiting